Antibody-drug conjugates (ADCs) have fundamentally transformed the landscape of modern oncology, evolving from a theoretical "magic bullet" concept into a…
Read More
Gilead and Nucleai probe why target-positive tumors can still resist ADCs
Antibody-drug conjugates (ADCs) have fundamentally transformed the landscape of modern oncology, offering a sophisticated "seek-and-destroy" mechanism that couples the precision…
Read More
Nucleai and Sirona Dx Forge Strategic Alliance to Revolutionize Spatial Proteomics for Drug Development
The pharmaceutical and biotechnology sectors are poised for a significant leap forward in drug development with the formation of a…
Read More
